These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation. Fujita T JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577725 [No Abstract] [Full Text] [Related]
43. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Sclafani F; Iyer R; Cunningham D; Starling N Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418 [TBL] [Abstract][Full Text] [Related]
45. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Ahn DH; Ko AH; Meropol NJ; Bekaii-Saab TS Am Soc Clin Oncol Educ Book; 2015; ():e222-7. PubMed ID: 25993177 [TBL] [Abstract][Full Text] [Related]
46. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707 [No Abstract] [Full Text] [Related]
48. [How I treat ... An advanced pancreatic cancer]. Polus M; Jerusalem G; Sautois B; Silvestre RM; Fillet G Rev Med Liege; 2002 Mar; 57(3):131-4. PubMed ID: 12014258 [TBL] [Abstract][Full Text] [Related]
49. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case. Turner K; Levi Sandri GB; Boucher E; Hénno S; Le Prisé E; Meunier B; Boudjema K; Sulpice L Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e29-31. PubMed ID: 25288453 [No Abstract] [Full Text] [Related]
50. A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy. Seino S; Tsuchiya A; Natsui M Gastroenterology; 2016 Feb; 150(2):e11-3. PubMed ID: 26718170 [No Abstract] [Full Text] [Related]
51. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Strobel O; Büchler MW Nat Rev Gastroenterol Hepatol; 2013 Apr; 10(4):203-5. PubMed ID: 23478386 [No Abstract] [Full Text] [Related]
52. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Bisht S; Brossart P; Feldmann G Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472 [TBL] [Abstract][Full Text] [Related]
53. Multimodality treatment of locally advanced pancreatic cancer. Wagener DJ; de Mulder PH; Wils JA Ann Oncol; 1994; 5 Suppl 3():81-6. PubMed ID: 8204534 [TBL] [Abstract][Full Text] [Related]
54. Active Systemic Treatment of Pancreatic Cancer. Tempero M J Natl Compr Canc Netw; 2017 May; 15(5S):723-725. PubMed ID: 28515255 [TBL] [Abstract][Full Text] [Related]
56. [Use of polyplatillen in chemotherapy of advanced pancreatic cancer]. Iatsenko LD; Lial'kin SA; Maĭdanevych NM Klin Khir; 2008 Jul; (7):20-3. PubMed ID: 19048815 [TBL] [Abstract][Full Text] [Related]
57. A pancreatic mass in a patient with nausea and vomiting. Extrapulmonary small cell carcinoma of the pancreas. Choi EH; Coyle W Gastroenterology; 2011 Mar; 140(3):e5-6. PubMed ID: 21276764 [No Abstract] [Full Text] [Related]
58. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma? Kourie HR; Gharios J; Kattan J Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286 [No Abstract] [Full Text] [Related]
59. Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice. Giuliani J; Bonetti A Recenti Prog Med; 2017 Mar; 108(3):152-154. PubMed ID: 28398410 [No Abstract] [Full Text] [Related]